Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient
The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reporte...
Saved in:
Main Authors: | Jorge Avila, Huseyin Berk Degirmenci, Pamela Contreras Chavez, Elisabeth M. Battinelli, Jorge Fleisher |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2023/7877536 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Building public confidence in innovative mRNA vaccines
by: Jia Hu, et al.
Published: (2025-01-01) -
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
by: Amparo L. Figueroa, et al.
Published: (2025-12-01) -
Immunogenicity of HIV-1 <i>Env</i> mRNA and <i>Env-Gag</i> VLP mRNA Vaccines in Mice
by: Qi Ma, et al.
Published: (2025-01-01) -
BNT162b2 versus mRNA-1273 mRNA COVID-19 vaccines as the third booster for the patients with underlying cancer
by: Amnuay Kleebayoon, et al.
Published: (2023-12-01) -
Myocarditis following mRNA COVID‐19 vaccination: call for endomyocardial biopsy
by: Daniel Kiblboeck, et al.
Published: (2022-06-01)